As expected, we found that MEK inhibition resulted in a concentration‐dependent reduction in ERK1/2 (pT202/Y204), a downstream substrate of MEK, in CD19+ CLL cells (Fig. 2A, left panel, green curves). The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.